Warner Chilcott Announces FDA Approval of New Oral Contraceptive

Warner Chilcott Announces FDA Approval of New Oral Contraceptive

DUBLIN, Ireland, April 22, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc
(Nasdaq:WCRX) today announced that the United States Food and Drug
Administration (FDA) has approved MINASTRIN^TM 24 FE (norethindrone acetate
and ethinyl estradiol capsules and ferrous fumarate capsules) for the
prevention of pregnancy. MINASTRIN 24 FE is manufactured for Warner Chilcott
by a third party. The Company does not expect to be in a position to
commercially launch MINASTRIN 24 FE during 2013.

About MINASTRIN 24 FE

MINASTRIN 24 FE is indicated for use by females of reproductive age to prevent
pregnancy.

Important Safety Information

Cigarette smoking increases the risk of serious cardiovascular events from
combination oral contraceptive (COC) use. This risk increases with age,
particularly in women over 35 years of age, and with the number of cigarettes
smoked. For this reason, COCs should not be used by women who are over 35
years of age and smoke.

For information on dosage and administration, contraindications, warnings and
precautions, adverse reactions, and other important safety and other
prescribing information, see http://www.wcrx.com/pdfs/pi/pi_minastrin24fe.pdf.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently
focused on the women's healthcare, gastroenterology, urology and dermatology
segments of the branded pharmaceuticals market, primarily in North America. We
are a fully integrated company with internal resources dedicated to the
development, manufacture and promotion of our products.

WCRX-G

Forward Looking Statements

This press release contains forward-looking statements, including statements
concerning our industry, our operations, our anticipated financial performance
and financial condition and our business plans, growth strategy and product
development efforts. These statements constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. The words "may," "might," "will,"
"should," "estimate," "project," "plan," "anticipate," "expect," "intend,"
"outlook," "believe" and other similar expressions are intended to identify
forward-looking statements. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of their dates. These
forward-looking statements are based on estimates and assumptions by our
management that, although we believe to be reasonable, are inherently
uncertain and subject to a number of risks and uncertainties. The following
represent some, but not necessarily all, of the factors that could cause
actual results to differ from historical results or those anticipated or
predicted by our forward-looking statements: our substantial indebtedness,
including increases in the LIBOR rates on our variable-rate indebtedness above
the applicable floor amounts; competitive factors and market conditions in the
industry in which we operate, including the approval and introduction of
generic or branded products that compete with our products; our ability to
protect our intellectual property; a delay in qualifying any of our
manufacturing facilities that produce our products, production or regulatory
problems with either our own manufacturing facilities or those of third party
manufacturers, packagers or API suppliers upon whom we may rely for some of
our products or other disruptions within our supply chain; pricing pressures
from reimbursement policies of private managed care organizations and other
third party payors, government sponsored health systems and regulatory
reforms, and the continued consolidation of the distribution network through
which we sell our products; changes in tax laws or interpretations that could
increase our consolidated tax liabilities; government regulation, including
U.S. and foreign health care reform, affecting the development, manufacture,
marketing and sale of pharmaceutical products, including our ability and the
ability of companies with whom we do business to obtain necessary regulatory
approvals; adverse outcomes in our outstanding litigation, regulatory or
arbitration matters or an increase in the number of such matters to which we
are subject; the loss of key senior management or scientific staff; our
ability to manage the growth of our business by successfully identifying,
developing, acquiring or licensing new products at favorable prices and
marketing such new products; our ability to obtain regulatory approval and
customer acceptance of new products, and continued customer acceptance of our
existing products; and the other risks identified in our periodic filings
including our Annual Report on Form 10-K for the year ended December31, 2012,
and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive.
In addition, in light of these risks and uncertainties, the matters referred
to in our forward-looking statements may not occur. We undertake no obligation
to publicly update or revise any forward-looking statement as a result of new
information, future events or otherwise, except as may be required by law.

CONTACT: Rochelle Fuhrmann
         Investor Relations
         973-442-3281
         rfuhrmann@wcrx.com

Warner Chilcott Logo